SYK and B-cell chronic lymphocytic leukemia: Preclinical studies of other Syk inhibitors such as R406 and two highly selective Syk inhibitors (PRT318 and P505-15) demonstrated responses in CLL cells supporting the development of a novel and active therapeutic approach for CLL and other selected B-cell malignancies [84,85].